Hematologic Neoplasms
Leukemia
Pancreatic Neoplasms
Clusters of Pneumocystis carinii pneumonia: analysis of person-to-person transmission by genotyping. (1/1889)
Genotyping at the internal transcribed spacer (ITS) regions of the nuclear rRNA operon was performed on isolates of P. carinii sp. f. hominis from three clusters of P. carinii pneumonia among eight patients with haematological malignancies and six with HIV infection. Nine different ITS sequence types of P. carinii sp. f. hominis were identified in the samples from the patients with haematological malignancies, suggesting that this cluster of cases of P. carinii pneumonia was unlikely to have resulted from nosocomial transmission. A common ITS sequence type was observed in two of the patients with haematological malignancies who shared a hospital room, and also in two of the patients with HIV infection who had prolonged close contact on the ward. In contrast, different ITS sequence types were detected in samples from an HIV-infected homosexual couple who shared the same household. These data suggest that person-to-person transmission of P. carinii sp. f. hominis may occur from infected to susceptible immunosuppressed patients with close contact within hospital environments. However direct transmission between patients did not account for the majority of cases within the clusters, suggesting that person-to-person transmission of P. carinii sp. f. hominis infection may be a relatively infrequent event and does not constitute the major route of transmission in man. (+info)TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor. (2/1889)
The TEL/PDGFbetaR fusion protein is expressed as the consequence of a recurring t(5;12) translocation associated with chronic myelomonocytic leukemia (CMML). Unlike other activated protein tyrosine kinases associated with hematopoietic malignancies, TEL/PDGFbetaR is invariably associated with a myeloid leukemia phenotype in humans. To test the transforming properties of TEL/PDGFbetaR in vivo, and to analyze the basis for myeloid lineage specificity in humans, we constructed transgenic mice with TEL/PDGFbetaR expression driven by a lymphoid-specific immunoglobulin enhancer-promoter cassette. These mice developed lymphoblastic lymphomas of both T and B lineage, demonstrating that TEL/PDGFbetaR is a transforming protein in vivo, and that the transforming ability of this fusion is not inherently restricted to the myeloid lineage. Treatment of TEL/PDGFbetaR transgenic animals with a protein tyrosine kinase inhibitor with in vitro activity against PDGFbetaR (CGP57148) resulted in suppression of disease and a prolongation of survival. A therapeutic benefit was apparent both in animals treated before the development of overt clonal disease and in animals transplanted with clonal tumor cells. These results suggest that small-molecule tyrosine kinase inhibitors may be effective treatment for activated tyrosine kinase-mediated malignancies both early in the course of disease and after the development of additional transforming mutations. (+info)The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. (3/1889)
We analysed 57 patients with non-myeloid malignancies who received a non-purged autologous PBSCT. All had similar mobilisation and conditioning regimens. A high prior chemotherapy score and the number of chemotherapy lines used (P = 0.015 and P = 0.01, respectively) were adverse predictors of CD34 cell yields. Lower CD34 values (P = 0.002) were seen in patients treated with potent stem cell toxins (BCNU, melphalan, CCNU and mustine), designated toxicity factor 4 agents (TF4). All patients infused with grafts containing CD34 cell doses between 1.0 and 2.0 x 10(6)/kg (range 1.25-1.90) engrafted by day 51. The only variable associated with slow platelet recovery was exposure to TF4 (P = 0.007). The majority of patients with CD34 >1.0 x 10(6)/kg achieved rapid and sustained engraftment and the only predictive factor of delayed recovery is prior exposure to stem cell toxins. Potential PBSCT candidates should if possible avoid first line and salvage chemotherapy containing TF4 drugs. We therefore advocate a minimum CD34 threshold of >1.0 x 10(6)/kg in patients without extensive prior chemoradiotherapy, and > or = 2.0 x 10(6)/kg in all other patients. (+info)Central venous catheter exchange by guidewire for treatment of catheter-related bacteraemia in patients undergoing BMT or intensive chemotherapy. (4/1889)
Current guidelines for the treatment of catheter-related bacteraemia (CRB) advise against central venous catheter (CVC) exchange because of the potential risk of prolonging infection. However, there are no consistent data proving this recommendation. We evaluated prospectively the usefulness of CVC exchange by guidewire for the treatment of CRB in patients undergoing BMT or intensive chemotherapy. CVC exchange was considered when fever and positive blood cultures persisted after 2 days of adequate antimicrobial therapy and no potential source of bacteraemia other than CVC could be identified. The guidewire exchange was preceded and followed by a slow infusion of adequate antimicrobial therapy. Bacteraemia was confirmed as catheter-related by demonstrating concordance between isolates from the tip and blood cultures by pulsed-field electrophoresis of genomic DNA. This procedure was performed in 19 episodes of bacteraemia during a 1-year period. Fourteen episodes (74%) were catheter-related and 71% of these were due to coagulase-negative staphylococci. Guidewire replacement was accomplished uneventfully 4 days after development of sepsis (range 3-6). In all cases, clinical signs of sepsis disappeared in less than 24 h after replacement. Definitive catheter withdrawal was carried out a median of 16 days (range 3-42) after guidewire exchange; in all cases, the tip culture was negative. We conclude that CVC replacement by guidewire under adequate antimicrobial therapy may be a reasonable option for the treatment of CRB when antimicrobial therapy alone has been unsuccessful. (+info)Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. (5/1889)
To evaluate the efficacy and safety of itraconazole oral solution for preventing fungal infections, a randomized, placebo-controlled, double-blind, multicenter trial was conducted: 405 neutropenic patients with hematologic malignancies were randomly assigned to receive either itraconazole, 2.5 mg/kg every 12 hours (201 patients), or placebo (204 patients). Proven and suspected deep fungal infection occurred in 24% of itraconazole recipients and in 33% of placebo recipients, a difference of 9 percentage points (95% confidence interval [CI], 0.6% to 22.5%; P = .035). Fungemia due to Candida species was documented in 0.5% of itraconazole recipients and in 4% of placebo recipients, a difference of 3.5 percentage points (95% CI, 0.5% to 6%; P = .01). Deaths due to candidemia occurred in none of the itraconazole recipients compared with 4 placebo recipients, a difference of 2 percentage points (95% CI, 0.05% to 4%; P = .06). Aspergillus infection was documented in four itraconazole recipients (one death) and one placebo recipient (one death). Side effects causing drug interruption occurred in 18% of itraconazole recipients and 13% of placebo recipients. Itraconazole oral solution was well-tolerated and effectively prevented proven and suspected deep fungal infection as well as systemic infection and death due to Candida species. (+info)Possible carcinogenic effects of X-rays in a transgenerational study with CBA mice. (6/1889)
A lifetime experiment using 4279 CBA/J mice was carried out to investigate whether the pre-conceptual exposure of sperm cells to X-ray radiation or urethane would result in an increased cancer risk in the untreated progeny, and/or increased susceptibility to cancer following exposure to a promoting agent. The study consisted of four main groups, namely a control group (saline), a urethane group (1 mg/g body wt) and two X-ray radiation groups (1 Gy, 2 Gy). At 1, 3 and 9 weeks after treatment, the males of these four parental groups were mated with untreated virgin females. The offspring of each parental group was divided into two subgroups: one received s.c. urethane (0.1 mg/g body wt once) as a promoter, the other saline, at the age of 6 weeks. All animals were evaluated for the occurrence of tumours. K-ras oncogene and p53 tumour suppressor gene mutations were investigated in frozen lung tumour samples. The female offspring of male parents exposed to X-rays 1 week before their mating showed a trend towards a higher tumour incidence of the haematopoietic system than the F1 controls. In addition, a higher percentage of bronchioloalveolar adenocarcinomas in male offspring born to irradiated paternals mated 1 week after X-ray treatment points to a plausible increased sensitivity of post-meiotic germ cell stages towards transgenerational carcinogenic effects. On the other hand, no increased tumour incidence and malignancy were observed in the offspring born to irradiated paternals mated 3 and 9 weeks after X-ray treatment. Paternal urethane treatment 1, 3 and 9 weeks prior to conception did not result in significantly altered incidence or malignancy of tumours of the lung, liver and haematopoietic tissue in the offspring. K-ras mutations increased during tumour progression from bronchioloalveolar hyperplasia to adenoma. Codon 61 K-ras mutations were more frequent in lung tumours of urethane-promoted progeny from irradiated parents than from control parents. P53 mutations were absent from these lung alterations. (+info)Human herpesvirus 8 in hematologic diseases. (7/1889)
Human herpesvirus type 8 (HHV-8), also known as Kaposi's sarcoma-associated herpesvirus (KSHV) is a new member of the g-herpesvirus family. It is an unusual herpesvirus in that it carries a large number of genes that encode oncoproteins or cell signaling proteins. In addition to being the causative agent of both HIV-associated and non-HIV-associated Kaposi's sarcoma this DNA tumor virus has been implicated in the pathogenesis of several diseases. These include multiple myeloma (MM), Waldenstom's macroglobulinemia (WM), multicentric Castleman's disease (MCD), body cavity-based lymphoma (BCBL), and various other conditions such as sarcoidosis and pemphigus. While the causative role of the viral infection is fairly certain in the development of BCBL and multicentric Castleman's disease, HHV-8 may act through a different mechanism to induce plasma cell malignancies. It has been suggested though the finding is still controversial - that infection of bone marrow stromal dendritic cells by HHV-8 might be a key factor in the etiology and pathogenesis of monoclonal gammopathies. The aim of this review is to provide a short introduction into the tumorigenic potential of HHV-8 as well as to detail the available data and possible mechanisms on the involvement of this virus in different hematologic diseases. (+info)Ultrasound B-mode changes in the uterus and ovaries and Doppler changes in the uterus after total body irradiation and allogeneic bone marrow transplantation in childhood. (8/1889)
Internal genitalia and uterine blood flow were assessed by ultrasound in 12 females 4.0-10.9 years after total body irradiation and allogeneic bone marrow transplantation for childhood leukaemia or lymphoma. Median age of the participants was 12.7 years (range 6.1-17.6) at bone marrow transplantation and 21.5 years (11.6-25.6) at the follow-up study. At follow-up all had entered puberty and 11/12 females had experienced the menarche. Eight females received sex steroid replacement therapy, three had spontaneous pubertal development and one woman experienced symptoms of estrogen deficiency. Median uterine and ovarian volumes were significantly reduced to -2.6 standard deviation scores (SDS) (-6.3 to -0.6), P = 0.002, and -2.6 SDS (-4.8 to -0.5), P = 0.002, respectively, compared with normal controls. Follicles were only detectable in two individuals. Uterine blood flow was impaired, as a systolic blood flow could be measured in 6/9 individuals, and a diastolic blood flow in 1/9 females. Our results indicate that the prescribed dosage of hormone replacement therapy, which was sufficient to induce bleeding and suppress other stigmata of premature menopause, was inadequate to generate normal uterine growth. In order to achieve uterine growth higher doses of hormone replacement therapy may be required. Our results confirm pelvic ultrasound as a reliable tool for investigation of internal female genitalia; however, in an infertility setting further tests are indicated. (+info)Hematologic neoplasms, also known as hematological malignancies, are a group of diseases characterized by the uncontrolled growth and accumulation of abnormal blood cells or bone marrow cells. These disorders can originate from the myeloid or lymphoid cell lines, which give rise to various types of blood cells, including red blood cells, white blood cells, and platelets.
Hematologic neoplasms can be broadly classified into three categories:
1. Leukemias: These are cancers that primarily affect the bone marrow and blood-forming tissues. They result in an overproduction of abnormal white blood cells, which interfere with the normal functioning of the blood and immune system. There are several types of leukemia, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML).
2. Lymphomas: These are cancers that develop from the lymphatic system, which is a part of the immune system responsible for fighting infections. Lymphomas can affect lymph nodes, spleen, bone marrow, and other organs. The two main types of lymphoma are Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).
3. Myelomas: These are cancers that arise from the plasma cells, a type of white blood cell responsible for producing antibodies. Multiple myeloma is the most common type of myeloma, characterized by an excessive proliferation of malignant plasma cells in the bone marrow, leading to the production of abnormal amounts of monoclonal immunoglobulins (M proteins) and bone destruction.
Hematologic neoplasms can have various symptoms, such as fatigue, weakness, frequent infections, easy bruising or bleeding, weight loss, swollen lymph nodes, and bone pain. The diagnosis typically involves a combination of medical history, physical examination, laboratory tests, imaging studies, and sometimes bone marrow biopsy. Treatment options depend on the type and stage of the disease and may include chemotherapy, radiation therapy, targeted therapy, immunotherapy, stem cell transplantation, or a combination of these approaches.
Leukemia is a type of cancer that originates from the bone marrow - the soft, inner part of certain bones where new blood cells are made. It is characterized by an abnormal production of white blood cells, known as leukocytes or blasts. These abnormal cells accumulate in the bone marrow and interfere with the production of normal blood cells, leading to a decrease in red blood cells (anemia), platelets (thrombocytopenia), and healthy white blood cells (leukopenia).
There are several types of leukemia, classified based on the specific type of white blood cell affected and the speed at which the disease progresses:
1. Acute Leukemias - These types of leukemia progress rapidly, with symptoms developing over a few weeks or months. They involve the rapid growth and accumulation of immature, nonfunctional white blood cells (blasts) in the bone marrow and peripheral blood. The two main categories are:
- Acute Lymphoblastic Leukemia (ALL) - Originates from lymphoid progenitor cells, primarily affecting children but can also occur in adults.
- Acute Myeloid Leukemia (AML) - Develops from myeloid progenitor cells and is more common in older adults.
2. Chronic Leukemias - These types of leukemia progress slowly, with symptoms developing over a period of months to years. They involve the production of relatively mature, but still abnormal, white blood cells that can accumulate in large numbers in the bone marrow and peripheral blood. The two main categories are:
- Chronic Lymphocytic Leukemia (CLL) - Affects B-lymphocytes and is more common in older adults.
- Chronic Myeloid Leukemia (CML) - Originates from myeloid progenitor cells, characterized by the presence of a specific genetic abnormality called the Philadelphia chromosome. It can occur at any age but is more common in middle-aged and older adults.
Treatment options for leukemia depend on the type, stage, and individual patient factors. Treatments may include chemotherapy, targeted therapy, immunotherapy, stem cell transplantation, or a combination of these approaches.
Pancreatic neoplasms refer to abnormal growths in the pancreas that can be benign or malignant. The pancreas is a gland located behind the stomach that produces hormones and digestive enzymes. Pancreatic neoplasms can interfere with the normal functioning of the pancreas, leading to various health complications.
Benign pancreatic neoplasms are non-cancerous growths that do not spread to other parts of the body. They are usually removed through surgery to prevent any potential complications, such as blocking the bile duct or causing pain.
Malignant pancreatic neoplasms, also known as pancreatic cancer, are cancerous growths that can invade and destroy surrounding tissues and organs. They can also spread (metastasize) to other parts of the body, such as the liver, lungs, or bones. Pancreatic cancer is often aggressive and difficult to treat, with a poor prognosis.
There are several types of pancreatic neoplasms, including adenocarcinomas, neuroendocrine tumors, solid pseudopapillary neoplasms, and cystic neoplasms. The specific type of neoplasm is determined through various diagnostic tests, such as imaging studies, biopsies, and blood tests. Treatment options depend on the type, stage, and location of the neoplasm, as well as the patient's overall health and preferences.
Neoplasms are abnormal growths of cells or tissues in the body that serve no physiological function. They can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slow growing and do not spread to other parts of the body, while malignant neoplasms are aggressive, invasive, and can metastasize to distant sites.
Neoplasms occur when there is a dysregulation in the normal process of cell division and differentiation, leading to uncontrolled growth and accumulation of cells. This can result from genetic mutations or other factors such as viral infections, environmental exposures, or hormonal imbalances.
Neoplasms can develop in any organ or tissue of the body and can cause various symptoms depending on their size, location, and type. Treatment options for neoplasms include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy, among others.
Acute myeloid leukemia
Mixed-phenotype acute leukemia
Cyclophosphamide
Blastic plasmacytoid dendritic cell neoplasm
Tumor lysis syndrome
Smouldering myeloma
Monoclonal gammopathy
Clonal hypereosinophilia
Plasmacytoid dendritic cell
Myeloid leukemia
Mycoplasma genitalium
French-American-British classification
Peter Valent
Plasma cell dyscrasias
Waldenström macroglobulinemia
Tumors of the hematopoietic and lymphoid tissues
Bing-Neel syndrome
Pel-Ebstein fever
Cold autoimmune hemolytic anemia
Plasmacytoma
Indolent T cell lymphoproliferative disorder of the gastrointestinal tract
Primary effusion lymphoma
Philadelphia chromosome
Obstetrical bleeding
Mediastinal germ cell tumor
KDM1A
Anaerobic infection
Engineered CAR T cell delivery
Extramedullary hematopoiesis
Platelet-derived growth factor receptor A
Candidatus Neoehrlichia mikurensis Infection in Patient with Antecedent Hematologic Neoplasm, Spain - Volume 29, Number 8...
Allogeneic Transplantation for Hematologic Neoplasms in Adults - The ASCO Post
Download Flow Cytometry Immunohistochemistry And Molecular Genetics For Hematologic Neoplasms
Flow Cytometry, Immunochemistry and Molecular Genetics for Hematologic Neoplasms | 9781608316168 - Zookal AU
Acute myeloid leukemia - Wikipedia
Risk of malignancy among patients with rheumatic conditions
Orphanet: EuroBloodNet: European Reference Network on Rare Hematological Diseases
CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one...
Chronic myeloid leukemia (CML) is certainly a hematologic neoplasm using a - NF-κB signaling in inflammation and cancer
Diffuse Large B-Cell Lymphoma (DLBCL): Practice Essentials, Background, Pathophysiology
American Journal of Case Reports | A Rare Case of Systemic Mastocytosis with Associated Hematologic Neoplasm (SM-AHN) Involving...
Aspectos clínicos y epidemiológicos de las leucemias
myeloid leukemia associated with Down Syndrome - Ontology Report - Rat Genome Database
Levonorgestrel (IUD) (Professional Patient Advice) - Drugs.com
Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies | Haematologica
Paraneoplastic Syndromes: Practice Essentials, Pathophysiology, Etiology
PDF) TAC versus FAC as Adjuvant Chemotherapy for High-risk Node-negative Breast Cancer: Results from the GEICAM 9805 Trial
Cell Transplantation Summary Report | CureHunter
Pathology and Laboratory Medicine, Diagnostic Tests
Benzene | Medical Management Guidelines | Toxic Substance Portal | ATSDR
Continuation With Statin Therapy and the Risk of Primary Cancer: A Population-Based Study | Blogs | CDC
Portal Regional da BVS
TP53 Genetic Test: MedlinePlus Medical Test
An HPC-Driven Data Science Platform to Speed-up Time Series Data Analysis of Patients with the Acute Respiratory Distress...
Katarzyna Jamieson - UNC Lineberger
122501000119101 - Lymphoproliferative disorder following lung transplant - SNOMED CT
KoreaMed
Effect of cancer on outcome of COVID-19 patients: a systematic review and meta-analysis of studies of unvaccinated patients |...
Malignancies2
- In a series of 635 patients with extragonadal germ cell tumors, 17 patients developed hematologic malignancies at a median of 6 months after the extragonadal germ cell tumor was diagnosed. (health.am)
- Ataxia telangiectasia (AT) is a rare autosomal recessive disease, characterised by cerebella ataxia, immunodeficiency, increased sensitivity to ionising radiation, and a predisposition to malignancies, especially lymphoid neoplasms. (bmj.com)
Molecular Genetics For Hematologic Neoplasms1
- Would you Consider to carry PSYCHOLOGICAL download flow cytometry immunohistochemistry and molecular genetics for hematologic neoplasms or handling in this subject? (binaryinfo.com)
Malignancy4
- We report a confirmed case of Candidatus Neoehrlichia mikurensis infection in a woman in Spain who had a previous hematologic malignancy. (cdc.gov)
- Where a defined exposure to past chemotherapy, radiotherapy, toxin or hematologic malignancy is known, this is termed secondary AML. (wikipedia.org)
- Scholars@Duke publication: How Caregivers Cope and Adapt When a Family Member Is Diagnosed With a Hematologic Malignancy: Informing Supportive Care Needs. (duke.edu)
- Informal family caregivers (FCs) of adults with various diseases including hematologic malignancy (HM) experience low quality of life and psychological well-being. (duke.edu)
Myeloproliferative neoplasm2
- There was evident dysgranulopoiesis that raised a provisional diagnosis of myelodysplastic/myeloproliferative neoplasm. (amjcaserep.com)
- 3 Myelofibrosis (MF) refers to the Philadelphia chromosome ( BCR-ABL1 )-negative myeloproliferative neoplasm (MPN) originating at the level of the multipotent hematopoietic stem cell. (haematologica.org)
Lymphoma1
- In our practice, hematologic neoplasms are mainly lymphoproliferative syndromes and the most common varieties are non-Burkitt non Hodgkin lymphoma, high grade lymphomas, chronic lymphocytic lymphoma and multiple myeloma. (bvsalud.org)
Myeloid3
- Response to treatment is certainly measured with regards to hematologic cytogenetic and molecular variables as described in Desk 2 [2 13 Desk 2 Procedures of response in chronic myeloid leukemia and prognostic significance [2 13 Imatinib was initially approved in america in 2001 for the treating the advanced stages of CML. (healthcarecoremeasures.com)
- Acute myeloid leukemias (AMLs) are heterogeneous hematologic neoplasms characterized by myeloblast or promyelocyte proliferation without normal differentiation. (koreamed.org)
- In the recent fifth edition of the World Health Organization classification, similar to the recent update to the International Consensus Classification, the category was renamed to "myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions" and both classifications added novel subtypes with new JAK2 rearrangements (e.g. (nature.com)
Diagnosis1
- Immunophenotyping is the most powerful tool in the routine diagnosis of hematologic neoplasms. (jekkle.com.au)
Liver Neoplasms1
- Percutaneous ethanol injection (PEI) for liver neoplasms when criteria above are not met. (aetna.com)
Germ cell6
- Hematologic Neoplasia A unique association between mediastinal nonseminomatous germ cell tumors and a variety of hematologic neoplasms is now well described. (health.am)
- All hematologic neoplasms developed in the 287 patients with mediastinal nonseminomatous germ cell tumors, for a 2% incidence in this group. (health.am)
- Recent evidence indicates that the hematologic neoplasms in this setting are not treatment related, but rather arise from clones of malignant lymphoblasts or myeloblasts contained within the mediastinal germ cell tumor. (health.am)
- More importantly, several patients have had an identical chromosomal abnormality (an isochromosome of the short arm of chromosome 12) in the neoplastic cells from the mediastinal germ cell tumor and the hematologic neoplasm, providing strong evidence for a common origin. (health.am)
- However, the specific association of leukemias and other hematologic neoplasms with mediastinal nonseminomatous germ cell tumors, rather than with all germ cell tumors, remains unexplained. (health.am)
- In addition to hematologic neoplasia, several cases of idiopathic thrombocytopenia in association with mediastinal nonseminomatous germ cell tumors have been reported. (health.am)
Mortality1
- The pooled mortality OR for hematologic neoplasms was 2.14 (95% CI 1.87-2.44, I 2 20.8%, 8 studies). (elifesciences.org)
Flow Cytometry3
- This download flow cytometry immunohistochemistry and molecular genetics for hematologic is summarised arrived as cause of BMC Health Services Research world 11 today 2, 2011: biomedical concern: illuminating the Seaweed premise into series rebirth hospital and contracting. (binaryinfo.com)
- Amazon Giveaway is you to deliver many rivers in download flow cytometry immunohistochemistry and molecular genetics for hematologic to send attempt, load your Philosophy, and add ergodic issues and cookies. (binaryinfo.com)
- As download flow cytometry immunohistochemistry and molecular genetics for hematologic of the perspective, India's recipe wrote that a ergodic departure of the stakeholder warned from due concepts. (binaryinfo.com)
Transplantation1
- To complement The ASCO Post 's continued comprehensive coverage of the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on allogeneic transplantation for hematologic neoplasms in adults. (ascopost.com)
Diseases2
- Patients with hematologic myeloproliferative neoplasms (MPNs)-a group of rare blood diseases that include myelofibrosis, essential thrombocythemia (ET), and polycythemia vera (PV)-should take a more active role in their treatment plan, according to experts in oncology pharmacy who participated in a Pharmacy Times clinical forum at ASCO 2023 in Chicago, Illinois. (pharmacytimes.com)
- Mutations on epigenetic regulator genes are common in clonal hematopoiesis and may be a risk factor for HEMATOLOGIC NEOPLASMS and other cardiovascular diseases. (bvsalud.org)
Immunotherapy1
- Modulation and response of the immune system are of interest in cancer treatment due to the success of immunotherapy in the treatment of various neoplasms. (spandidos-publications.com)
Bone Marrow1
- A number of studies indicate that bone marrow fibrosis is an adverse prognostic variable in myeloproliferative neoplasms. (haematologica.org)
Leukemia1
- 16 had aggressive systemic mastocytosis, 57 had systemic mastocytosis with an associated hematologic neoplasm, and 16 had mast-cell leukemia. (uni-koeln.de)
Patients4
- Since then, several case series and individual cases of patients with Candidatus N. mikurensis infections have been described, mainly in persons who were immunosuppressed because of hematologic neoplasms, splenectomies, or immunosuppressive drug treatment ( 3 - 9 ). (cdc.gov)
- Despite a slew of barriers with patient management, pharmacists have the training and resources to advocate for better patient care and help patients with hematologic myeloproliferative neoplasms advocate for themselves. (pharmacytimes.com)
- Le protocole utilisé dans le traitement du myélome multiple a été le VMCD-REV à 76,92% avec pour réponse thérapeutique complète chez 6 patients, 3 réponses partielles et 4 en cours de traitement. (bvsalud.org)
- This was a descriptive retrospective study lasting 2 years 3 months from January 1st, 2018 to March 31st, 2020 concerning 80 patients with hematologic neoplasms who were managed in the CNRAO. (bvsalud.org)
Systemic2
- Systemic mastocytosis (SM) with an associated hematologic neoplasm (SM-AHN) comprises 5% to 40% of cases of SM. (amjcaserep.com)
- BACKGROUND Advanced systemic mastocytosis comprises rare hematologic neoplasms that are associated with a poor prognosis and lack effective treatment options. (uni-koeln.de)
Abnormal1
- Hematologic neoplasms are abnormal and anarchic proliferations of hematopoietic cells with a medullary or peripheral starting point. (bvsalud.org)
Syndromes1
- Paraneoplastic syndromes are rare disorders that are triggered by an altered immune system response to a neoplasm. (medscape.com)
Patient1
- Median survival was only 5 months after the hematologic disorder was diagnosed, and no patient survived for more than 2 years. (health.am)
Cancers1
- Hematologic neoplasms represented 2.2% of cancers (80/3650) at CNRAO, giving an annual incidence of 26.66 cases. (bvsalud.org)
Treatment1
- This Clinical Policy Bulletin addresses treatment approaches for liver and other neoplasms. (aetna.com)
20181
- Il s'agissait d'une étude rétrospective descriptive d'une durée de 2 ans 3 mois allant du 1er janvier 2018 au 31 Mars 2020 portant sur 80 dossiers de malades porteurs d'hémopathies malignes et prise en charge dans le centre. (bvsalud.org)
Rarely1
- All types of hematologic neoplasms have been previously reported, although CML has been rarely encountered. (amjcaserep.com)